GO:0019840 isoprenoid binding: Mechanism, Genes

Isoprenoid binding (GO:0019840) is a molecular_function term that describes the selective, non-covalent interaction of a protein or other macromolecule with an isoprenoid compound. Isoprenoids are a vast class of natural products built from isoprene (2-methylbuta-1,3-diene) units, including farnesyl pyrophosphate (FPP), geranylgeranyl pyrophosphate (GGPP), and their derivatives. This binding activity is central to the post-translational modification known as isoprenylation, in which a lipid group is covalently attached to cysteine residues near the C-terminus of target proteins, thereby promoting membrane association and protein-protein interactions. Beyond covalent modification, isoprenoid binding also encompasses non-covalent recognition events that regulate enzyme activity, receptor signaling, and metabolic flux. For researchers, GO:0019840 provides a functional annotation that connects diverse proteins to the mevalonate pathway and its downstream products. The term is particularly relevant to cancer biology, metabolic disorders, and infectious disease, because isoprenoid-binding proteins such as Ras, Rho, and Rab GTPases require lipid modification for their oncogenic or regulatory functions. Recent chemoproteomic studies using geranyl pyrophosphate probes have revealed that many proteins beyond the classical prenyltransferases can bind isoprenoids, suggesting that this molecular function is more widespread than previously appreciated. Understanding the structural and mechanistic basis of isoprenoid binding is therefore essential for developing inhibitors that target these interactions. This article synthesizes authoritative QuickGO annotation data with verified PubMed literature to provide a research-grade overview of GO:0019840. It covers the definition, biological significance, key genes, regulatory mechanisms, disease associations, and experimental models, with a focus on how CRISPR-based approaches can be used to dissect the causal roles of isoprenoid-binding proteins.

According to the Gene Ontology, GO:0019840 (isoprenoid binding) is defined as the binding to an isoprenoid compound, isoprene (2-methylbuta-1,3-diene) or compounds containing or derived from linked isoprene (3-methyl-2-butenylene) residues. In practical terms, this means the ability of a protein or macromolecule to recognize and interact with molecules such as farnesyl pyrophosphate, geranylgeranyl pyrophosphate, or isoprenoid-modified lipids through non-covalent forces. This binding can serve structural, catalytic, or regulatory roles, and it is distinct from the covalent attachment of isoprenoid groups to proteins, although the two processes are often functionally linked.

Isoprenoid binding is fundamentally important because it governs the interaction of proteins with a major class of cellular lipids that control membrane localization, signal transduction, and metabolic homeostasis. Many small GTPases, including Ras, Rho, and Rab family members, require isoprenoid binding for their function, and dysregulation of these proteins is directly linked to cancer, neurodegeneration, and immune disorders. Furthermore, isoprenoid-binding proteins are emerging as targets for therapeutic intervention, as evidenced by the development of prenyltransferase inhibitors and chemoproteomic probes that map isoprenoid-binding sites across the proteome. Understanding this molecular function is therefore critical for both basic cell biology and translational medicine.

The following genes encode proteins that exhibit isoprenoid binding activity or are directly involved in isoprenoid metabolism and recognition, as supported by published literature.

Isoprenoid binding is regulated at multiple levels. The availability of isoprenoid substrates is controlled by the mevalonate pathway, which is feedback-regulated by sterol levels and by the activity of HMG-CoA reductase. In yeast, phosphate limitation and pyruvate decarboxylase activity can redirect metabolic flux towards the isoprenoid pathway, thereby influencing the abundance of isoprenoid ligands for binding proteins. Additionally, the expression and post-translational modification of isoprenoid-binding proteins themselves can be regulated by signaling pathways such as the mTOR pathway, although direct evidence for mTOR regulation of isoprenoid binding is limited. Chemoproteomic studies have shown that the isoprenoid-binding proteome is dynamic and can be modulated by metabolic state.

Isoprenoid binding is critically involved in cancer because many oncoproteins, including Ras and Rho GTPases, require prenylation for membrane localization and activity. Mutations in KRAS, HRAS, and NRAS that lock the proteins in active states are found in a wide range of human cancers, and their function depends on farnesylation. Inhibitors of farnesyltransferase and geranylgeranyltransferase have been developed as anticancer agents, although clinical success has been limited by compensatory prenylation. Chemoproteomic profiling of geranyl pyrophosphate-binding proteins has revealed additional targets that may contribute to cancer cell metabolism and proliferation.

Isoprenoid derivatives of lysophosphatidylcholines enhance insulin and GLP-1 secretion through lipid-binding GPCRs, linking isoprenoid binding to glucose homeostasis and type 2 diabetes. This suggests that modulating isoprenoid binding could have therapeutic potential for metabolic diseases. Additionally, statins, which inhibit the mevalonate pathway and reduce isoprenoid synthesis, are widely used to lower cholesterol and have pleiotropic effects on metabolism.

Protein isoprenylation is essential for the function of Rab GTPases, which regulate vesicular trafficking and autophagy in neurons. Defects in isoprenoid binding or prenylation can lead to impaired autophagic flux and accumulation of protein aggregates, contributing to neurodegenerative diseases such as Parkinson's and Alzheimer's. However, direct evidence linking specific isoprenoid-binding proteins to neurodegeneration requires further study.

Some pathogens rely on isoprenoid binding for virulence. For example, the malaria parasite uses isoprenoid biosynthesis pathways that are essential for its survival, and isoprenoid-binding proteins in parasites are potential drug targets. Manoalide, a marine natural product, inhibits phospholipase A2 and has anti-inflammatory properties, but its relationship to isoprenoid binding is not well established.

Chemoproteomic profiling using geranyl pyrophosphate probes allows global identification of isoprenoid-binding proteins in cell lysates or live cells. This method typically employs click chemistry to attach a reporter tag to the probe, enabling enrichment and mass spectrometry-based identification. It is a powerful approach for discovering new isoprenoid-binding proteins and for mapping binding sites.

In vitro lipid-binding assays, such as fluorescence polarization or isothermal titration calorimetry, can measure the affinity of purified proteins for isoprenoid ligands. These assays are useful for validating binding specificity and for testing the effects of mutations.

Genome-wide CRISPR knockout or activation screens can identify genes that modulate isoprenoid binding or sensitivity to isoprenoid pathway inhibitors. Such screens are particularly useful for uncovering synthetic lethal interactions with prenylation inhibitors.

Fluorescence microscopy of tagged isoprenoid-binding proteins can reveal their subcellular localization and how it changes upon isoprenoid binding or prenylation. This approach is often combined with knock-in of fluorescent tags using CRISPR.

Researchers studying isoprenoid binding-related genes often need to determine whether a candidate gene is causally involved in a specific cellular process or disease. CRISPR-based models provide the most direct way to establish causality by manipulating the gene of interest in its native genomic context. EDITGENE offers a comprehensive suite of services to support these investigations, from knockout to precise point mutations and library screening.

GO:0019840 (isoprenoid binding) is a fundamental molecular function that governs the interaction of proteins with a diverse class of lipids derived from isoprene. It is essential for the localization and activity of many signaling proteins, including Ras and Rho GTPases, and is implicated in cancer, metabolic disorders, and neurodegeneration. Advances in chemoproteomics have expanded the known repertoire of isoprenoid-binding proteins, opening new avenues for drug discovery. CRISPR-based models, such as knockout, point mutation, knock-in, and overexpression, are indispensable for establishing causality and for validating therapeutic targets. EDITGENE provides end-to-end services to support these studies, from custom cell line generation to library screening and bioinformatics analysis.